19.12.2019 • News

Brenntag Boosts UK Presence with Tan Buy

Brenntag führt neue operative Geschäftsstruktur mit zwei globalen... — Brenntag führt neue operative Geschäftsstruktur mit zwei globalen Geschäftsbereichen ein. Foto: Brenntag

Leading chemical distributor Brenntag has boosted its presence in the UK with the acquisition of Tan International.

Headquartered in Perth, Scotland, Tan distributes and blends specialty and industrial chemicals and ingredients for industries such as food and beverage, pharmaceutical, agriculture and energy.

“The company’s strong relationships with large key accounts as well as its diverse portfolio support our ambition to expand further in focus industries such as food & nutrition, agriculture and oil & gas,” commented Karsten Beckmann, member of Brenntag’s management board and CEO Brenntag Europe, Middle East and Africa.

Anthony Gerace, managing director mergers & acquisitions at the German group, added that the Perth site’s excellent location will also enable Brenntag to enhance its regional coverage and offer improved service capabilities across the region.

The acquired business is expected to generate sales of approximately £21 million in the 2019 financial year.

Just two months ago, Brenntag agreed to buy Brazilian chemical distributor Quimisa and its logistics subsidiary Quimilog.

Company

Brenntag SE

Messeallee 11
45131 Essen
Germany

Company contact

I am interested in:

an offer
a callback
detailed information

Your request

salutation first name last name

country phone email

Please note our data protection information for the contact form.

Free Virtual Event

CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.